Richardcyoung.com

  • Home
  • Debbie Young
  • Jimmy Buffett
  • Key West
  • Your Survival Guy
  • How We Are Different
  • Paris
  • About Us
    • Foundation Principles
    • Contributors
  • Investing
    • You’ve Read The Last Issue of Intelligence Report, Now What?
  • The Swiss Way
  • My Rifles
  • Dividends and Compounding
  • Your Security
  • Dick Young
  • Dick’s R&B Top 100
  • Liberty & Freedom Map
  • Bank Credit & Money
  • Your Survival Guy’s Super States
  • NNT & Cholesterol
  • Your Health
  • Ron Paul
  • US Treasury Yield Curve: My Favorite Investor Tool
  • Anti-Gun Control
  • Anti-Digital Currency
  • Joel Salatin & Alfie Oakes
  • World Gold Mine Production
  • Fidelity & Wellington Since 1971
  • Hillsdale College
  • Babson College
  • Contact Us

Will New COVID Treatment Pill End Forced Vaccinations?

December 23, 2021 By The Editors

By Javidestock @ Shutterstock.com

Americans across the country are losing their jobs or access to their favorite shops and businesses thanks to draconian vaccine mandates handed down by politicians with little regard for science. Despite the many supplements that can help COVID sufferers, the FDA has chosen to push people to get vaccinated. Now the FDA has given an emergency use authorization to Pfizer’s new COVID-treatment drug, Paxlovid. Will the FDA’s acceptance of this new COVID treatment mean an end to forced vaccinations? Fox Business reports:

The Food and Drug Administration approved an emergency use authorization on Wednesday for Pfizer’s oral antiviral treatment drug against COVID-19, Paxlovid.

Under the emergency use authorization, the treatment is for oral use in adults and children 12 years or older who weigh at least 40 kilograms or about 88 pounds and who are at high risk for progressing to severe COVID-19.

However, availability of Paxlovid will be limited at first and the Department of Health and Human Services will begin allocating around 65,000 courses of treatment in the first week of January to all 50 states and territories, as well as government agencies and Health Resources and Services Administration-funded health centers.

According to the Department of Health and Human Services, the initial allocations were made on a pro rata basis, and are being delivered at no cost to state and territorial health departments.

For example, California will receive 6,180 courses, while Missouri, for example, will receive 980 during the first week of allocations.

The Department of Defense, Department of State, Immigration and Customs Enforcement, and the Indian Health Service will also receive allocations of the drug.

Two-hundred Health Resources and Services Administration-funded health centers will receive 9,750 courses of Paxlovid during the first week’s allocation, which will help the department’s focus on equity.

“State and territorial health departments will allocate product to dispensing sites across their jurisdictions, and the distributor will ship product directly to receiving sites, which include pharmacies, doctors’ offices, clinics, hospitals, urgent care centers, and local health departments,” the Department of Health and Human Services announcement states.

The department expects that the supply of Pfizer’s Paxlovid will increase, as an additional 200,000 courses are expected in January, and shipments will occur every two weeks.

Pfizer announced in November that it would supply the U.S. government with 10 million treatment courses of Paxlovid between 2021 and 2022.

According to the Food and Drug Administration, Paxlovid is only available through a prescription and should be taken as soon as possible following a diagnosis of COVID-19 and within five days of symptoms beginning.

“Today’s authorization introduces the first treatment for COVID-19 that is in the form of a pill that is taken orally — a major step forward in the fight against this global pandemic,” Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research, said in a statement. “This authorization provides a new tool to combat COVID-19 at a crucial time in the pandemic as new variants emerge and promises to make antiviral treatment more accessible to patients who are at high risk for progression to severe COVID-19.”

On our COVID-19 page, you can see where cases are occurring in America today.

Related Posts

  • Colleges to Require COVID Vaccinations for In Person Learning
  • COVID Deaths Unfortunate but Insignificant
  • Covid-19’s Hidden Hobbies
  • Dozens of Treatment Options for Viral Infections
  • Author
  • Recent Posts
The Editors
The Editors
The Editors
Latest posts by The Editors (see all)
  • Are California Politicians Abetting the Violence? - June 11, 2025
  • Democrats Slowly Realizing Transgender Campaign Was a Mistake - June 9, 2025
  • Memorial Day Remembrance - May 26, 2025

Dick Young’s Must Reads

  • You May Be Surprised by America’s “Least Woke City”
  • SVB – There’s Panic in the Air
  • Interest Rates Your Dad Would Be Proud Of
  • My Smith & Wesson Revolvers Home Defense Team
  • Russian Black Sea Fleet Decimated
  • DIGITAL ID: You Are More than a Soulless Digital Identity
  • America’s Silent Army with 423M Guns
  • Joel Salatin and Alfie Oakes, America’s Food Kings
  • The Biden Cabal Wants to Stop the Use of Clean, Safe, Domestic Natural Gas
  • Why Black Lives Matter Needs to Be Shut Down

Our Most Popular Posts

  • Whoa, Hang on Here. There’s Trouble in Culver City
  • Is Salt Bad for You?
  • RON PAUL: Can Musk and Trump Reconcile?
  • $25 Million Down; $175 Million to Go
  • Saving Western Civilization
  • Graduating from Work to Retirement #19: A Teacher for Life
  • No More NSAIDS for Back Pain?
  • There Are Only Two Ways to Cut Entitlements
  • The Federal Reserve Finally Killed the Penny
  • Ukraine’s Attack Underlines Need for Trump-Style Border Control

Compensation was paid to utilize rankings. Click here to read full disclosure.

RSS Youngresearch.com

  • Graduating from Work to Retirement Special Bonus: God Only Knows
  • US Secures LNG Export Deals Worth $200 Billion
  • High-Voltage Cable Crunch Hits Global Electrification
  • May PPI Lower than Expected
  • Graduating from Work to Retirement #20: Life in Reverse
  • US Inflation Eases to 0.1% in May
  • DOE Focuses on Nuclear and AI Innovation
  • Trump Delivers Lower Inflation and Rising Wages
  • Natural Gas Power Growth Slows, but Big Gains Possible by 2028
  • Graduating from Work to Retirement #19: A Teacher for Life

RSS Yoursurvivalguy.com

  • Graduating from Work to Retirement Special Bonus: God Only Knows
  • Private Equity: Moody’s Warns There’s Ample Cause for Concern
  • Your Survival Guy: Castle Hill, Newport
  • Containerized Missiles and the New Rules of War
  • Graduating from Work to Retirement #20: Life in Reverse
  • America’s Silent Army with 423M Guns
  • Top 10 Reasons to Own an AR-15
  • Graduating from Work to Retirement #19: A Teacher for Life
  • Can Luxury Ride AI to Success?
  • Market Timing Could Be Hazardous to Your Portfolio

US Treasury Yield Curve: My Favorite Investor Tool

My Key West Garden Office

Your Retirement Life: Traveling the Efficient Frontier

Live a Long Life

Your Survival Guy’s Mt. Rushmore of Investing Legends

“Then One Day the Grandfather was Gone”

Copyright © 2025 | Terms & Conditions | About Us | Dick Young | Archives